metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2
mGC or mGEJC - L1 - HER2 negative 1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive 4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population 4
mGC or mGEJC - L2 - PDL1 positive 1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative 1
mGC or mGEJC - M - HER2 neg/PDL1 positive 1
gene alteration defined cancer

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open